Earnings Summary

Alnylam Pharmaceuticals, Inc.’s revenue fell -33.26% since last year same period to $500.92Mn in the Q3 2024. On a quarterly growth basis, Alnylam Pharmaceuticals, Inc. has generated -24.08% fall in its revenue since last 3-months.

Alnylam Pharmaceuticals, Inc.’s net profit fell -175.51% since last year same period to $-111.57Mn in the Q3 2024. On a quarterly growth basis, Alnylam Pharmaceuticals, Inc. has generated -560.61% fall in its net profits since last 3-months.

Alnylam Pharmaceuticals, Inc.’s net profit margin fell -213.14% since last year same period to -22.27% in the Q3 2024. On a quarterly growth basis, Alnylam Pharmaceuticals, Inc. has generated -770.17% fall in its net profit margins since last 3-months.

Alnylam Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.93 - a 13.89% jump from last quarter’s estimates.

Alnylam Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at -0.93.

Alnylam Pharmaceuticals, Inc.’s earning per share (EPS) fell -175.65% since last year same period to -0.87 in the Q3 2024. This indicates that the Alnylam Pharmaceuticals, Inc. has generated -175.65% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Alnylam Pharmaceuticals, Inc.’s return on assets (ROA) stands at -0.03.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Alnylam Pharmaceuticals, Inc.’s return on equity (ROE) stands at -15.01.